Text size Moderna’s headquarters in Cambridge, Massachusetts. Joseph Prezioso / AFP / Getty Images Moderna’s announcement of positive data about a Phase 1 trial of its Covid-19 vaccine in May was met with skepticism by some experts, who noted that the company had not included many details about the trial’s …
Read More »
Text size Maddie Meyer / Getty Images Moderna’s shares have risen 239% so far this year, and the biotech company, which has no approved medications, has a market capitalization of more than $ 24 billion. But in a note sent out Monday morning, Jefferies analyst Michael Yee writes that the …
Read More »
Text size Joseph Prezioso / Getty Images Shares of Modern biotechnology fell 6.2% on Thursday afternoon after health news website Stat reported that the company was delaying the start of a Phase 3 trial of its experimental Covid-19 vaccine. The report, based on quotes from unidentified sources described as “investigators,” …
Read More »
Text size Daniel Acker / Bloomberg Shares of the large pharmaceutical company Pfizer continue to rise one day after the company revealed promising and detailed data on a trial of its experimental vaccine Covid-19. Analysts said the highly aggressive timeline the company outlined on Wednesday was exciting, but far from …
Read More »
Gilead Sciences Inc.’s COVID-19 drug remdesivir will cost much less than Wall Street analysts had predicted in a move that likely points to a more measured and responsible approach to the price of treatments and vaccines during the pandemic. Gilead GILD Shares, It gained 0.9% in trading on Monday following …
Read More »